The Christ Hospital Heart & Vascular Institute Heart Failure Symposium 2025

1. Overview
The Christ Hospital Heart & Vascular Institute Heart Failure Symposium 2025 delivers a cutting-edge review of advanced heart failure management, ranging from foundational medical therapies to the latest in mechanical circulatory support. The course highlights emerging device technologies, updates in heart transplantation, and novel pharmacological treatments for specific cardiomyopathies like amyloidosis and hypertrophic cardiomyopathy.
Course Date: 2025
2. Learning Objectives

Optimize foundational medical therapies to establish the most effective base for heart failure care.

Evaluate emerging research innovations and devices, including Doraya, Precardia, and WhiteSwell.

Discuss the latest 2025 updates in heart transplantation and advancements in LVAD pump design.

Apply new therapeutic strategies for amyloidosis and hypertrophic cardiomyopathy, including myosin inhibitors.

Manage acute failure with short-term support (ECMO, Impella) and explore the future of total artificial hearts (BIVACOR).

3. Target Audience

Best for heart failure specialists and cardiologists who want updates on transplant, MCS, amyloidosis, and emerging device therapies.

4. Topics

Medical Therapies- Forming the Most Effective Base

Research Innovations – Doraya, Precardia, WhiteSwell, Vectorius, CVRx

LVAD’s – Innovations in Management and Pump Design

Heart Transplantation – What’s New in 2025

Transcatheter Mitral and Tricuspid Devices – When to Intervene and How

Atrial Fibrillation and Heart Failure – General Approach in a Sick Population

Amyloidosis – The March of Cool Drugs

Hypertrophic Cardiomyopathy – Myosin Inhibitors and Beyond

Regenerative Therapies for Heart Failure – Successes and Challenges

ECMO – Indications, Exclusions, Management

Short-term Support – Impella, RVAD, IABP

Future of the Machines – BIVACOR